UBS Group AG Acquires 214,084 Shares of Immatics N.V. $IMTX

UBS Group AG increased its holdings in shares of Immatics N.V. (NASDAQ:IMTX) by 61.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 563,463 shares of the company’s stock after acquiring an additional 214,084 shares during the period. UBS Group AG’s holdings in Immatics were worth $5,916,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new position in shares of Immatics during the 4th quarter worth about $2,189,000. Baker BROS. Advisors LP boosted its position in Immatics by 18.9% during the third quarter. Baker BROS. Advisors LP now owns 12,094,094 shares of the company’s stock valued at $103,042,000 after purchasing an additional 1,925,193 shares during the last quarter. Jefferies Financial Group Inc. bought a new position in Immatics in the third quarter valued at approximately $10,181,000. Aberdeen Group plc increased its stake in shares of Immatics by 9.7% during the 3rd quarter. Aberdeen Group plc now owns 789,446 shares of the company’s stock worth $6,726,000 after purchasing an additional 69,860 shares during the last quarter. Finally, TD Asset Management Inc raised its holdings in shares of Immatics by 33.1% in the 3rd quarter. TD Asset Management Inc now owns 383,804 shares of the company’s stock valued at $3,270,000 after purchasing an additional 95,548 shares during the period. Institutional investors own 64.41% of the company’s stock.

Immatics Stock Up 4.9%

Shares of IMTX stock opened at $11.22 on Thursday. Immatics N.V. has a 12-month low of $4.93 and a 12-month high of $12.41. The company has a market capitalization of $1.50 billion, a PE ratio of -5.64 and a beta of 1.31. The firm has a 50 day moving average price of $10.53 and a two-hundred day moving average price of $10.17.

Immatics (NASDAQ:IMTX) last announced its earnings results on Tuesday, May 12th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.08). The firm had revenue of $8.81 million for the quarter, compared to the consensus estimate of $9.79 million. Immatics had a negative return on equity of 47.36% and a negative net margin of 572.35%. As a group, research analysts expect that Immatics N.V. will post -1.66 EPS for the current year.

Wall Street Analysts Forecast Growth

IMTX has been the subject of a number of research analyst reports. Wall Street Zen cut Immatics from a “hold” rating to a “sell” rating in a report on Saturday, May 2nd. Mizuho set a $25.00 price objective on Immatics in a research report on Thursday, February 19th. Jefferies Financial Group assumed coverage on Immatics in a research note on Monday, March 16th. They set a “buy” rating and a $18.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Immatics in a research note on Thursday, January 22nd. Finally, TD Cowen began coverage on Immatics in a report on Tuesday, April 28th. They set a “buy” rating for the company. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $19.00.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.